The Management of Cardiovascular Diseases in Patients with Hemophilia

 

 Buy Article Permissions and Reprints

ABSTRACT

Morbidity and mortality for cardiovascular disease are likely to be lower in patients with hemophilia than in the general male population. However, their clinical impact is increasing in parallel with the increase of life expectancy due to modern safe replacement treatments and the improvement of comprehensive care of these patients. No rigorous trial concerning treatment of ischemic coronary disease is currently available, and such studies are probably not feasible in this setting. Given the lack of evidence-based guidelines, the analysis of case reports describing management of coronary artery disease and cardiac surgery in hemophilic patients suggests that treatment strategies should be similar to those used in nonhemophilic subjects, provided that an adequate concentrate replacement is administered. On the whole, treatment should be tailored for balancing the actual thrombotic risk and the preexisting bleeding tendency, enhanced by the use of antithrombotic agents. In this review, the available information is discussed, together with the recent suggestions of experts developed to provide more uniform approaches and collection of data. Treatment of cardiovascular disease reflects the evolving scenario in which clinicians who treat hemophilia will have to extend their interactions with other specialists to confront the new challenges of the comprehensive care of aging hemophilic patients.

REFERENCES

• 1 Mannucci P M, Tuddenham E G. The hemophilias—from royal genes to gene therapy.  N Engl J Med. 2001;  344(23) 1773-1779
  CrossrefPubMedGoogle Scholar
• 2 Mejia-Carvajal C, Czapek E E, Valentino L A. Life expectancy in hemophilia outcome.  J Thromb Haemost. 2006;  4(3) 507-509
  CrossrefPubMedGoogle Scholar
• 3 Franchini M, Tagliaferri A, Mannucci P M. The management of hemophilia in elderly patients.  Clin Interv Aging. 2007;  2(3) 361-368
  PubMedGoogle Scholar
• 4 Stewart J W, Acheson J D. Atherosclerosis in a haemophiliac.  Lancet. 1957;  272 1121-1122
  PubMedGoogle Scholar
• 5 Meili E O, Straub P W, Lichtlen P, Frick P G. Myocardial infarction in a haemophiliac. Demonstration of coronary sclerosis by selective angiography.  Helv Med Acta. 1968;  34(3) 239-243
  PubMedGoogle Scholar
• 6 Small M, Jack A S, Lowe G D, Mutch A F, Forbes C D, Prentice C R. Coronary artery disease in severe haemophilia.  Br Heart J. 1983;  49(6) 604-607
  CrossrefPubMedGoogle Scholar
• 7 Rosendaal F R, Varekamp I, Smit C et al.. Mortality and causes of death in Dutch haemophiliacs, 1973–86.  Br J Haematol. 1989;  71(1) 71-76
  CrossrefPubMedGoogle Scholar
• 8 Triemstra M, Rosendaal F R, Smit C, Van der Ploeg H M, Briët E. Mortality in patients with hemophilia. Changes in a Dutch population from 1986 to 1992 and 1973 to 1986.  Ann Intern Med. 1995;  123(11) 823-827
  CrossrefPubMedGoogle Scholar
• 9 Srámek A, Kriek M, Rosendaal F R. Decreased mortality of ischaemic heart disease among carriers of haemophilia.  Lancet. 2003;  362(9381) 351-354
  CrossrefPubMedGoogle Scholar
• 10 Plug I, Van Der Bom J G, Peters M et al.. Mortality and causes of death in patients with hemophilia, 1992–2001: a prospective cohort study.  J Thromb Haemost. 2006;  4(3) 510-516
  CrossrefPubMedGoogle Scholar
• 11 Koumbarelis E, Rosendaal F R, Gialeraki A et al.. Epidemiology of haemophilia in Greece: an overview.  Thromb Haemost. 1994;  72(6) 808-813
  PubMedGoogle Scholar
• 12 Darby S C, Kan S W, Spooner R J et al.. Mortality rates, life expectancy, and causes of death in people with hemophilia A or B in the United Kingdom who were not infected with HIV.  Blood. 2007;  110(3) 815-825
  CrossrefPubMedGoogle Scholar
• 13 Soucie J M, Nuss R, Evatt B The Hemophilia Surveillance System Project Investigators et al. Mortality among males with hemophilia: relations with source of medical care.  Blood. 2000;  96(2) 437-442
  PubMedGoogle Scholar
• 14 Kulkarni R, Soucie J M, Evatt B L. Hemophilia Surveillance System Project Investigators . Prevalence and risk factors for heart disease among males with hemophilia.  Am J Hematol. 2005;  79(1) 36-42
  CrossrefPubMedGoogle Scholar
• 15 Tuinenburg A, Mauser-Bunschoten E P, Verhaar M C, Biesma D H, Schutgens R EG. Cardiovascular disease in patients with hemophilia.  J Thromb Haemost. 2009;  7(2) 247-254
  CrossrefPubMedGoogle Scholar
• 16 Srámek A, Reiber J HC, Gerrits W BJ, Rosendaal F R. Decreased coagulability has no clinically relevant effect on atherogenesis: observations in individuals with a hereditary bleeding tendency.  Circulation. 2001;  104(7) 762-767
  CrossrefPubMedGoogle Scholar
• 17 Sartori M T, Bilora F, Zanon E et al.. Endothelial dysfunction in haemophilia patients.  Haemophilia. 2008;  14(5) 1055-1062
  CrossrefPubMedGoogle Scholar
• 18 Franchini M. Thrombotic complications in patients with hereditary bleeding disorders.  Thromb Haemost. 2004;  92(2) 298-304
  PubMedGoogle Scholar
• 19 Schimpf K L, Zeltsch C, Zeltsch P. Myocardial infarction complicating activated prothrombin complex concentrate substitution in a patient with hemophilia A.  Lancet. 1982;  2 1043
  PubMedGoogle Scholar
• 20 Gruppo R A, Bove K E, Donaldson V H. Fatal myocardial necrosis associated with prothrombin-complex concentrate therapy in hemophilia A.  N Engl J Med. 1983;  309(4) 242-243
  CrossrefPubMedGoogle Scholar
• 21 Sullivan D W, Purdy L J, Billingham M, Glader B E. Fatal myocardial infarction following therapy with prothrombin complex concentrates in a young man with hemophilia A.  Pediatrics. 1984;  74(2) 279-281
  PubMedGoogle Scholar
• 22 Chavin S I, Siegel D M, Rocco Jr T A, Olson J P. Acute myocardial infarction during treatment with an activated prothrombin complex concentrate in a patient with factor VIII deficiency and a factor VIII inhibitor.  Am J Med. 1988;  85(2) 245-249
  CrossrefPubMedGoogle Scholar
• 23 Karayalcin G, Goldberg B, Cherrick I, Kurer C, Bierman F, Lanzkowsky P. Acute myocardial infarction complicating prothrombin complex concentrate therapy in an 8-year-old boy with hemophilia A and factor VIII inhibitor.  Am J Pediatr Hematol Oncol. 1993;  15(4) 416-419
  PubMedGoogle Scholar
• 24 Köhler M, Hellstern P, Lechler E, Uberfuhr P, Müller-Berghaus G. Thromboembolic complications associated with the use of prothrombin complex and factor IX concentrates.  Thromb Haemost. 1998;  80(3) 399-402
  PubMedGoogle Scholar
• 25 Iannaccaro P, Santoro R, Sottilotta G, Papaleo G, Muleo G. Thrombosis in hemophiliacs with prothrombotic molecular defect.  Clin Appl Thromb Hemost. 2005;  11(3) 359-360
  CrossrefPubMedGoogle Scholar
• 26 Siboni S M, Mannucci P M, Gringeri A et al.. Health status and quality of life of elderly persons with severe hemophilia born before the advent of modern replacement therapy.  J Thromb Haemost. 2009;  7(5) 780-786
  CrossrefPubMedGoogle Scholar
• 27 Miesbach W, Alesci S, Krekeler S, Seifried E. Comorbidities and bleeding pattern in elderly haemophilia A patients.  Haemophilia. 2009;  15(4) 894-899
  CrossrefPubMedGoogle Scholar
• 28 Girolami A, Ruzzon E, Fabris F et al.. Myocardial infarction and other arterial occlusions in hemophilia A patients. A cardiological evaluation of all 42 cases reported in the literature.  Acta Haematol. 2006;  116 120-125
  CrossrefPubMedGoogle Scholar
• 29 Girolami A, Randi M L, Ruzzon E, Zanon E, Girolami B. Myocardial infarction, other arterial thrombosis and invasive coronary procedures, in hemaophilia B: a critical evaluation of reported cases.  J Thromb Thrombolysis. 2005;  20(1) 43-46
  CrossrefPubMedGoogle Scholar
• 30 Aledort L M. Comparative thrombotic event incidence after infusion of recombinant factor VIIa versus factor VIII inhibitor bypass activity.  J Thromb Haemost. 2004;  2(10) 1700-1708
  CrossrefPubMedGoogle Scholar
• 31 Negrier C, Goudemand J, Sultan Y, Bertrand M, Rothschild C, Lauroua P. Multicenter retrospective study on the utilization of FEIBA in France in patients with factor VIII and factor IX inhibitors. French FEIBA Study Group. Factor Eight Bypassing Activity.  Thromb Haemost. 1997;  77(6) 1113-1119
  PubMedGoogle Scholar
• 32 Ehrlich H J, Henzl M J, Gomperts E D. Safety of factor VIII inhibitor bypass activity (FEIBA): 10-year compilation of thrombotic adverse events.  Haemophilia. 2002;  8(2) 83-90
  CrossrefPubMedGoogle Scholar
• 33 Franchini M, Zaffanello M, Veneri D. Recombinant factor VIIa. An update on its clinical use.  Thromb Haemost. 2005;  93(6) 1027-1035
  PubMedGoogle Scholar
• 34 Roberts H R. Recombinant factor VIIa (NovoSeven) and the safety of treatment.  Semin Hematol. 2001;  38(4, suppl 12) 48-50
  CrossrefPubMedGoogle Scholar
• 35 Lippi G, Montagnana M, Salvagno G L, Guidi G C. Potential value for new diagnostic markers in the early recognition of acute coronary syndromes.  CJEM. 2006;  8(1) 27-31
  PubMedGoogle Scholar
• 36 Antithrombotic Trialists’ Collaboration . Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients.  BMJ. 2002;  324(7329) 71-86
  CrossrefPubMedGoogle Scholar
• 37 Harrington R A, Becker R C, Cannon C P American College of Chest Physicians et al. Antithrombotic therapy for non-ST-segment elevation acute coronary syndromes: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition).  Chest. 2008;  133(6, suppl) 670S-707S
  CrossrefPubMedGoogle Scholar
• 38 Goodman S G, Menon V, Cannon C P, Steg G, Ohman E M, Harrington R A. American College of Chest Physicians . Acute ST-segment elevation myocardial infarction: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition).  Chest. 2008;  133(6, suppl) 708S-775S
  CrossrefPubMedGoogle Scholar
• 39 Moscucci M, Fox K A, Cannon C P et al.. Predictors of major bleeding in acute coronary syndromes: the Global Registry of Acute Coronary Events (GRACE).  Eur Heart J. 2003;  24(20) 1815-1823
  CrossrefPubMedGoogle Scholar
• 40 Warkentin T E, Kelton J G. Temporal aspects of heparin-induced thrombocytopenia.  N Engl J Med. 2001;  344(17) 1286-1292
  CrossrefPubMedGoogle Scholar
• 41 Merlini P A, Rossi M, Menozzi A et al.. Thrombocytopenia caused by abciximab or tirofiban and its association with clinical outcome in patients undergoing coronary stenting.  Circulation. 2004;  109(18) 2203-2206
  CrossrefPubMedGoogle Scholar
• 42 Mielke Jr C H, Britten A F. Use of aspirin or acetaminophen in hemophilia.  N Engl J Med. 1970;  282(22) 1270
  CrossrefPubMedGoogle Scholar
• 43 Quick A J. No aspirin for hemophiliacs.  N Engl J Med. 1971;  284(4) 218
  PubMedGoogle Scholar
• 44 MacKinlay N, Taper J, Renisson F, Rickard K. Cardiac surgery and catheterization in patients with haemophilia.  Haemophilia. 2000;  6(2) 84-88
  PubMedGoogle Scholar
• 45 Forman M B, Kopelman H A, Gleaton J H, Janco R L, Perry J M. Percutaneous transluminal coronary angioplasty in hemophilia.  Am Heart J. 1986;  111(1) 169-172
  CrossrefPubMedGoogle Scholar
• 46 Helft G, Metzger J P, Samama M M, Rothschild C, Batisse J P, Vacheron A. Coronary stenting in a hemophilic patient.  Thromb Haemost. 1997;  77(5) 1044-1045
  PubMedGoogle Scholar
• 47 Peerlinck K, Vermylen J. Acute myocardial infarction following administration of recombinant activated factor VII (Novo Seven) in a patient with haemophilia A and inhibitor.  Thromb Haemost. 1999;  82(6) 1775-1776
  PubMedGoogle Scholar
• 48 Alsolaiman M M, Chang K, Arjomand H, Oza R, Costacurta G. Acute left anterior descending artery occlusion in a hemophiliac A patient during recombinant factor VIII infusion: treatment with coronary angioplasty.  Catheter Cardiovasc Interv. 2000;  50(4) 468-472
  CrossrefPubMedGoogle Scholar
• 49 Au W Y, Jim M H, Lam C C. Unusual case of coronary artery disease in a patient with severe hemophilia B.  Am J Hematol. 2002;  69(2) 152-153
  CrossrefPubMedGoogle Scholar
• 50 Bovenzi F, De Luca L, Signore N, Fusco F, de Luca I. Abciximab for the treatment of an acute thrombotic coronary occlusion during stent implantation in a patient with severe hemophilia B.  Ital Heart J. 2003;  4(10) 728-730
  PubMedGoogle Scholar
• 51 Kerkhoffs J L, Atsma D E, Oemrawsingh P V, Eikenboom J, Van der Meer F JM. Acute myocardial infarction during substitution with recombinant factor VIII concentrate in a patient with mild haemophilia A.  Thromb Haemost. 2004;  92(2) 425-426
  PubMedGoogle Scholar
• 52 Virtanen R, Kauppila M, Itälä M. Percutaneous coronary intervention with stenting in a patient with haemophilia A and an acute myocardial infarction following a single dose of desmopressin.  Thromb Haemost. 2004;  92(5) 1154-1156
  PubMedGoogle Scholar
• 53 Arora U K, Dhir M, Cintron G, Strom J A. Successful multi-vessel percutaneous coronary intervention with bivalirudin in a patient with severe hemophilia A: a case report and review of literature.  J Invasive Cardiol. 2004;  16(6) 330-332
  PubMedGoogle Scholar
• 54 Krolick M A. Successful percutaneous coronary intervention in a patient with severe haemophilia A using bivalirudin as the sole procedural anticoagulant.  Haemophilia. 2005;  11(4) 415-417
  CrossrefPubMedGoogle Scholar
• 55 Smolka G, Kulach A, Dabek J, Szulc A, Gasior Z. Percutaneous coronary intervention with stent implantation in haemophilic A patient with unstable angina.  Haemophilia. 2007;  13(4) 428-431
  CrossrefPubMedGoogle Scholar
• 56 Ferrario C, Renders F, Cairoli A, Vuffray A, Spertini O, Angelillo-Scherrer A. Management of an acute coronary syndrome in a patient with severe haemophilia A.  Haemophilia. 2007;  13(6) 763-765
  CrossrefPubMedGoogle Scholar
• 57 Quintero D, Biria M, Meyers D G. Percutaneous coronary intervention in a patient with acute ST-elevation myocardial infarction and hemophilia A.  J Invasive Cardiol. 2008;  20(5) 240-241
  PubMedGoogle Scholar
• 58 Coppola A, De Simone C, Di Capua M et al.. Management of ischemic heart disease in hemophilic patients: new challenges from a case report and review of the literature [abstract].  Haemophilia. 2008;  14(Suppl 2) 127
  PubMedGoogle Scholar
• 59 Rivolta G F, Di Perna C, Franchini M et al.. Management of coronary artery disease in a severe haemophilia patient with high titre inhibitor and anaphylaxis.  Haemophilia. 2009;  15(5) 1161-1163
  CrossrefPubMedGoogle Scholar
• 60 Schutgens R EG, Tuinenburg A, Roosendaal G, Guyomi S H, Mauser-Bunschoten E P. Treatment of ischaemic heart disease in haemophilia patients: an institutional guideline.  Haemophilia. 2009;  15(4) 952-958
  CrossrefPubMedGoogle Scholar
• 61 Shaw S M, Fildes J E, Yonan N, Williams S G. Pleiotropic effects and cholesterol-lowering therapy.  Cardiology. 2009;  112(1) 4-12
  CrossrefPubMedGoogle Scholar
• 62 Antman E M, Cohen M, Radley D et al.. Assessment of the treatment effect of enoxaparin for unstable angina/non-Q-wave myocardial infarction. TIMI 11B-ESSENCE meta-analysis.  Circulation. 1999;  100(15) 1602-1608
  CrossrefPubMedGoogle Scholar
• 63 Ferguson J J, Califf R M, Antman E M SYNERGY Trial Investigators et al. Enoxaparin vs unfractionated heparin in high-risk patients with non-ST-segment elevation acute coronary syndromes managed with an intended early invasive strategy: primary results of the SYNERGY randomized trial.  JAMA. 2004;  292(1) 45-54
  CrossrefPubMedGoogle Scholar
• 64 Karthikeyan G, Mehta S R, Eikelboom J W. Fondaparinux in the treatment of acute coronary syndromes: evidence from OASIS 5 and 6.  Expert Rev Cardiovasc Ther. 2009;  7(3) 241-249
  CrossrefPubMedGoogle Scholar
• 65 Bittl J A, Chaitman B R, Feit F, Kimball W, Topol E J. Bivalirudin versus heparin during coronary angioplasty for unstable or postinfarction angina: Final report reanalysis of the Bivalirudin Angioplasty Study.  Am Heart J. 2001;  142(6) 952-959
  CrossrefPubMedGoogle Scholar
• 66 Maroo A, Lincoff A M. Bivalirudin in PCI: an overview of the REPLACE-2 trial.  Semin Thromb Hemost. 2004;  30(3) 329-336
  Article in Thieme ConnectPubMedGoogle Scholar
• 67 Harker L A, Boissel J P, Pilgrim A J, Gent M. Comparative safety and tolerability of clopidogrel and aspirin: results from CAPRIE. CAPRIE Steering Committee and Investigators. Clopidogrel versus aspirin in patients at risk of ischaemic events.  Drug Saf. 1999;  21(4) 325-335
  CrossrefPubMedGoogle Scholar
• 68 Cid A R, Zorio E, Haya S et al.. Treatment in a haemophiliac A patient with paroxysmal atrial fibrillation and ischemic heart disease.  Haemophilia. 2007;  13(6) 760-762
  CrossrefPubMedGoogle Scholar
• 69 Patrono C, Baigent C, Hirsh J, Roth G. American College of Chest Physicians . Antiplatelet drugs: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition).  Chest. 2008;  133(6, suppl) 199S-233S
  CrossrefPubMedGoogle Scholar
• 70 Levine G N, Kern M J, Berger P B et al.. Management of patients undergoing percutaneous coronary revascularization.  Ann Intern Med. 2003;  139(2) 123-136
  CrossrefPubMedGoogle Scholar
• 71 Iakovou I, Schmidt T, Bonizzoni E et al.. Incidence, prediction and outcome of thrombosis after successful implantation of drug-eluting stents.  JAMA. 2005;  293(17) 2126-2130
  CrossrefPubMedGoogle Scholar
• 72 Banerjee S, Varghese C, Samuel J et al.. Comparison of the impact of short (<1 year) and long-term (>or = 1 year) clopidogrel use following percutaneous coronary intervention on mortality.  Am J Cardiol. 2008;  102(9) 1159-1162
  CrossrefPubMedGoogle Scholar
• 73 Agostoni P, Biondi-Zoccai G G, de Benedictis M L et al.. Radial versus femoral approach for percutaneous coronary diagnostic and interventional procedures: systematic overview and meta-analysis of randomized trials.  J Am Coll Cardiol. 2004;  44 349-356
  CrossrefPubMedGoogle Scholar
• 74 Kinnaird T, Anderson R, Hill J, Thomas M. Bleeding during percutaneous intervention: tailoring the approach to minimise risk.  Heart. 2009;  95(1) 15-19
  CrossrefPubMedGoogle Scholar
• 75 Cantor W J, Puley G, Natarajan M K et al.. Radial versus femoral access for emergent percutaneous coronary intervention with adjunct glycoprotein IIb/IIIa inhibition in acute myocardial infarction—the RADIAL-AMI pilot randomized trial.  Am Heart J. 2005;  150(3) 543-549
  CrossrefPubMedGoogle Scholar
• 76 Koreny M, Riedmuller E, Nikfardjam M, Siostrzonek P, Mullner M. Arterial puncture closing devices compared with standard manual compression after cardiac catheterization: systematic review and meta-analysis.  JAMA. 2004;  291 350-357
  CrossrefPubMedGoogle Scholar
• 77 Kwa A T, Rogers J H. Current update on glycoprotein IIb-IIIa and direct thrombin inhibition in percutaneous coronary intervention for non-ST elevation acute coronary syndromes: balancing bleeding risk and antiplatelet efficacy.  J Interv Cardiol. 2008;  21(2) 107-117
  CrossrefPubMedGoogle Scholar
• 78 Lickfett L, Hagendorff A, Jung W, Pizzulli L, Brackmann H H, Lüderitz B. Acute posterior wall infarct after factor VIII concentrate administration to a patient with severe hemophilia A [in German].  Dtsch Med Wochenschr. 1998;  123(21) 658-662
  Article in Thieme ConnectPubMedGoogle Scholar
• 79 Tang M, Wierup P, Terp K, Ingerslev J, Sørensen B. Cardiac surgery in patients with haemophilia.  Haemophilia. 2009;  15(1) 101-107
  CrossrefPubMedGoogle Scholar
• 80 Legget P L, Doyle D, Smith W B et al.. Elective cardiac operation in a patient with severe haemophilia and acquired factor VIII antibodies.  J Thorac Cardiovasc Surg. 1984;  87(4) 556-560
  PubMedGoogle Scholar
• 81 Mazzucco A, Stellin G, Cantele P, Boschello M, Traldi A, Gallucci V. Repair of ventricular septal defect and aortic regurgitation associated with severe hemophilia B.  Ann Thorac Surg. 1986;  42(1) 97-99
  CrossrefPubMedGoogle Scholar
• 82 Raish R J, Witte D L, Goldsmith J C. Successful cardiac surgery following plasmapheresis in a patient with hemophilia B.  Transfusion. 1985;  25(2) 128-130
  CrossrefPubMedGoogle Scholar
• 83 Vander Woude J C, Milam J D, Walker W E, Houchin D P, Weiland A P, Cooley D A. Cardiovascular surgery in patients with congenital plasma coagulopathies.  Ann Thorac Surg. 1988;  46(3) 283-288
  CrossrefPubMedGoogle Scholar
• 84 Palanzo D A, Sadr F S. Coronary artery bypass grafting in a patient with haemophilia B.  Perfusion. 1995;  10 265-270
  CrossrefPubMedGoogle Scholar
• 85 De Bels D, Demeere J L, Dugauquier J, Louis P, Van der Vorst E. Continuous infusion of factor VIIIc during heart surgery in a patient with haemophilia A.  Eur J Anaesthesiol. 2004;  21(12) 984-986
  PubMedGoogle Scholar
• 86 Palareti G, Leali N, Coccheri S Italian Study on Complications of Oral Anticoagulant Therapy et al. Bleeding complications of oral anticoagulant treatment: an inception-cohort, prospective collaborative study (ISCOAT).  Lancet. 1996;  348(9025) 423-428
  CrossrefPubMedGoogle Scholar
• 87 Kaminishi Y, Aizawa K, Saito T, Misawa Y, Madoiwa S, Sakata Y. Modified Bentall operation in a patient with hemophilia A.  Jpn J Thorac Cardiovasc Surg. 2003;  51(2) 68-70
  CrossrefPubMedGoogle Scholar
• 88 Ghosh K, Shetty S. Anticoagulation in haemophilia patients with prosthetic valve replacement.  Haemophilia. 2004;  10(6) 743
  CrossrefPubMedGoogle Scholar
• 89 Dargaud Y, Meunier S, Negrier C. Haemophilia and thrombophilia: an unexpected association!.  Haemophilia. 2004;  10(4) 319-326
  CrossrefPubMedGoogle Scholar
• 90 Franchini M, Lippi G. Together we care: new challenges for global haemophilia treatment centers.  Indian J Med Res. 2009;  129(4) 345-347
  PubMedGoogle Scholar
• 91 Mauser-Bunschoten E P, Fransen Van De Putte D E, Schutgens R EG. Co-morbidity in the ageing haemophilia patient: the down side of increased life expectancy.  Haemophilia. 2009;  15(4) 853-863
  CrossrefPubMedGoogle Scholar

Massimo FranchiniM.D. 

Immunohematology and Transfusion Center

Department of Pathology and Laboratory Medicine, University Hospital of Parma, Parma, Italy

Email: mfranchini@ao.pr.it